Pazopanib

Pazopanib
Clinical data
Pronunciation	/pæˈzoʊpənɪb/ paz-OH-pə-nib
Trade names	Votrient
AHFS/Drugs.com	Monograph
MedlinePlus	a610013
License data	US DailyMed: Pazopanib;
Pregnancy; category	AU: D;
Routes of; administration	By mouth
ATC code	L01EX03 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Bioavailability	21% (14–39%)
Protein binding	>99.5%
Metabolism	Liver: CYP3A4 (major), 1A2 and 2C8 (minor)
Elimination half-life	30.9±4 hours
Excretion	Faeces (primary), urine (<4%)
Identifiers
	IUPAC name 5-({4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]pyrimidin-2-yl}amino)-2-methylbenzenesulfonamide;
CAS Number	444731-52-6 ; as HCl: 635702-64-6 ;
PubChem CID	11525740;
IUPHAR/BPS	5698;
DrugBank	DB06589 ;
ChemSpider	9700526 ;
UNII	7RN5DR86CK; as HCl: 33Y9ANM545 ;
KEGG	D05380 ;
ChEBI	CHEBI:71219 ;
ChEMBL	ChEMBL477772 ;
CompTox Dashboard (EPA)	DTXSID8048733 ;
Chemical and physical data
Formula	C21H23N7O2S
Molar mass	437.52 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=S(=O)(N)c1c(ccc(c1)Nc2nccc(n2)N(c4ccc3c(nn(c3C)C)c4)C)C;
	InChI InChI=1S/C21H23N7O2S.ClH/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16;/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25);1H ; Key:MQHIQUBXFFAOMK-UHFFFAOYSA-N ;
	(what is this?) (verify)

Pazopanib, sold under the brand name Votrient, is an anti-cancer medication marketed worldwide by Novartis. It is a potent and selective multi-targeted receptor tyrosine kinase inhibitor that blocks tumour growth and inhibits angiogenesis. It has been approved for renal cell carcinoma and soft tissue sarcoma by numerous regulatory administrations worldwide.

Clinical data

Pronunciation	/pæˈzoʊpənɪb/ paz-OH-pə-nib
Trade names	Votrient
AHFS/Drugs.com	Monograph
MedlinePlus	a610013
License data	US DailyMed: Pazopanib
Pregnancy category	AU: D
Routes of administration	By mouth
ATC code	L01EX03 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) CA: ℞-only UK: POM (Prescription only) US: ℞-only EU: Rx-only
Pharmacokinetic data
Bioavailability	21% (14–39%)
Protein binding	>99.5%
Metabolism	Liver: CYP3A4 (major), 1A2 and 2C8 (minor)
Elimination half-life	30.9±4 hours
Excretion	Faeces (primary), urine (<4%)
Identifiers
IUPAC name 5-({4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]pyrimidin-2-yl}amino)-2-methylbenzenesulfonamide
CAS Number	444731-52-6^N as HCl: 635702-64-6^Y
PubChem CID	11525740
IUPHAR/BPS	5698
DrugBank	DB06589^N
ChemSpider	9700526^Y
UNII	7RN5DR86CK as HCl: 33Y9ANM545^Y
KEGG	D05380^N
ChEBI	CHEBI:71219^N
ChEMBL	ChEMBL477772^N
CompTox Dashboard (EPA)	DTXSID8048733
Chemical and physical data
Formula	C₂₁H₂₃N₇O₂S
Molar mass	437.52 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES O=S(=O)(N)c1c(ccc(c1)Nc2nccc(n2)N(c4ccc3c(nn(c3C)C)c4)C)C
InChI InChI=1S/C21H23N7O2S.ClH/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16;/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25);1H^Y Key:MQHIQUBXFFAOMK-UHFFFAOYSA-N^Y
^NY (what is this?) (verify)